CClinicalTrials.gg
RecruitingNCT07063147TICM-SCPUpdated Jul 18, 2025

TTE Improves Clinical Management of Stable Chest Pain

An observational study in Transthorcic Echocardiography, Stable Angina Pectoris and Coronary Artery Disease, sponsored by Tianjin Chest Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Tianjin Chest Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Study summary

The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.

02

Conditions studied

  • Transthorcic Echocardiography
  • Stable Angina Pectoris
  • Coronary Artery Disease
  • Major Adverse Cardiac Events
  • Invasive Coronary Angiography
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were referred for TTE for the assessment of SCP suspected of CAD.

Inclusion criteria

  • symptomatic patients with SCP suspected of obstructive CAD.
  • referred for TTE for the assessment of SCP.
  • ≥18 years of age.
  • signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • acute coronary syndromes
  • previous CAD or coronary revascularization
  • nonsinus rhythm
  • cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • TTE

    Diagnostic Test: TTE

Interventions

  • Diagnostic testTTE

    All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.

05

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events

    Time frame: 10 years

Secondary outcomes

  1. Invasive coronary angiography

    Invasive coronary angiography occurred at follow-up after TTE, attributed to TTE results or unplanned.

    Time frame: 10 years

  2. Medication prescription

    Change for medication prescription of antiplatelet agents, anti-ischemic drugs, lipid-lowering agents, angiotensin-converting enzyme inhibition and so on, attributed to TTE results or unplanned,

    Time frame: 10 years

  3. Coronary revascularization

    PTCA, PCI or CABG occurred at follow-up after TTE, attributed to TTE results or unplanned.

    Time frame: 10 years

06

Study locations

1 of 1 sites recruiting
  • Tianjin Chest Hospital
    Tianjin, China
    Recruiting
07

Registry details

Key details

Study ID
NCT07063147
Lead sponsor
Tianjin Chest Hospital
Responsible party
Zhou Jia (Principal Investigator, Tianjin Chest Hospital) — Principal investigator
First posted
Jul 14, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Jul 18, 2025

Study contacts

Jia Zhou
Contact
zhoujiawenzhang@126.com
+8615522485560

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion